Since CXCL5 is known to slow the progression of atherosclerosis, strategies that target sdLDL particles could enhance the protective effects of CXCL5, offering potential benefits for the management and treatment of atherosclerotic CVD. This evidence concerns the gene CXCL5 and atherosclerosis.